


What is claimed is:

1. This invention relates to compounds comprising Formula I:

5



Formula I

wherein:

R¹ is (C₁₋₆)alkyl;

10 R² is halogen or -OR';

R³ is hydrogen or -OR';

R' is hydrogen, (C₁₋₆)alkyl, or SO₂R'';

R'' is (C₁₋₆)alkyl, haloalkyl,

15 aryl or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with a group selected from (C₁₋₆)alkyl, halo, haloalkyl, cyano, nitro, alkylsulfonyl, and alkylsulfonylamino;

20 R⁴ is (i) (C₁₋₆)alkyl, (ii) aryl, heterocyclyl, or heteroaryl, wherein said aryl, heterocyclyl or heteroaryl groups are optionally substituted with a group selected from (C₁₋₆)alkyl, halo, haloalkyl, (C₁₋₆)alkoxy, cyano, amino, mono- or di alkylamino, nitro, alkylsulfonyl, alkylcarbonyl, urea, alkylcarbonylamino, alkylsulfonylamino, alkylaminosulfonyl, alkoxy carbonyl, heterocyclyl and heteroaryl, or

(iii) -NR⁵R⁶; and

R⁵ and R⁶ are independently of each other hydrogen, (C₁₋₆)alkyl,

25 aryl or heterocyclyl; wherein said aryl or heterocyclyl groups are optionally substituted with (C₁₋₆)alkyl, halo, haloalkyl, cyano, (C₁₋₆)alkoxy, and alkylsulfonyl;

or an individual isomer, a racemic or non-racemic mixture of isomers, or an acceptable salt or solvate thereof.

2. The compound of Claim 1, wherein R^2 is (C_{1-6}) alkoxy and R^3 is hydrogen.
3. The compound of Claim 1, wherein R^2 is (C_{1-6}) alkoxy and R^3 is (C_{1-6}) alkoxy.
4. The compound of Claim 1, wherein R^2 is $-OSO_2R''$ and R^3 is hydrogen.
5. The compound of Claim 1, wherein R^2 is hydroxy and R^3 is hydrogen.
6. The compound of Claim 1, wherein R^2 is halogen and R^3 is hydrogen.
7. The compound of Claim 1 wherein R^4 is (C_{1-6}) alkyl.
8. The compound of Claim 7, wherein R^1 is ethyl or propyl.
9. The compound of Claim 8, wherein R^2 is $-OR'$, and R^3 is $-OR'$ or hydrogen.
10. The compound of Claim 1, wherein R^4 is an aryl group.
11. The compound of Claim 10, wherein R^4 is phenyl optionally substituted with a group selected from (C_{1-6}) alkyl, halo, haloalkyl, (C_{1-6}) alkoxy, cyano, amino, mono- or di alkylamino, nitro, alkylsulfonyl, alkylcarbonyl, urea, alkylcarbonylamino, alkylsulfonylamino, alkylaminosulfonyl, alkoxycarbonyl, heterocyclyl and heteroaryl.
12. The compound of Claim 10, wherein R^1 is ethyl or propyl.
13. The compound of Claim 11, wherein R^1 is ethyl or propyl.

14. The compound of Claim 13, wherein R² is -OR', and R³ is -OR' or hydrogen.
15. The compound of Claim 1, wherein R⁴ is a heteroaryl group.
- 5 16. The compound of Claim 15, wherein R⁴ is selected from furanyl, thiophenyl, isooxazolyl, oxazolyl, imidazolyl, and pyrazolyl, all optionally substituted with one or two (C₁₋₆) alkyl.
17. The compound of Claim 15, wherein R¹ is ethyl or propyl.
- 10 18. The compound of Claim 16, wherein R¹ is ethyl or propyl.
19. The compound of Claim 18, wherein R² is -OR', and R³ is -OR' or hydrogen.
- 15 20. The compound of Claim 1, wherein R⁴ is a heterocyclyl group.
21. The compound of Claim 20, wherein R⁴ is piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, or diazepanyl, all optionally substituted with one or two (C₁₋₆)alkyl or alkylcarbonyl groups.
- 20 22. The compound of Claim 20, wherein R⁴ is piperidin-4-yl, optionally substituted with one or two (C₁₋₆)alkyl groups or alkylcarbonyl groups.
23. The compound of Claim 20, wherein R⁴ is piperidin-1-yl, optionally substituted
- 25 with one or two (C₁₋₆)alkyl groups.
24. The compound of Claim 20, wherein R⁴ is pyrrolidin-1-yl, optionally substituted with one or two (C₁₋₆)alkyl groups.
- 30 25. The compound of Claim 20, wherein R⁴ is [1,4]-diazepany-1-yl, optionally substituted with one or two (C₁₋₆)alkyl groups.

26. The compound of Claim 20, wherein R⁴ is piperazin-1-yl, optionally substituted with one or two (C₁₋₆)alkyl groups.
- 5 27. The compound of Claim 20, wherein R⁴ is morpholinyl, optionally substituted with one or two (C₁₋₆)alkyl groups.
28. The compound of Claim 20, wherein R¹ is ethyl or propyl.
- 10 29. The compound of Claim 21, wherein R¹ is ethyl or propyl.
30. The compound of Claim 29, wherein R² is -OR', and R³ is -OR' or hydrogen.
31. The compound of Claim 1, wherein R⁴ is -NR⁵R⁶.
- 15 32. The compound of Claim 31, wherein R⁵ is (C₁₋₆)alkyl, and R⁶ is hydrogen or (C₁₋₆)alkyl.
33. The compound of Claim 31, wherein R¹ is ethyl or propyl.
- 20 34. The compound of Claim 33, wherein R² is -OR', and R³ is -OR' or hydrogen.
35. The compound of Claim 1, comprising:
 {4-[(7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-
25 piperazin-1-yl-methanone;
 {4-[(7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-
morpholin-4-yl-methanone;
 {4-[(6,7-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-
yl}-piperidin-4-yl-methanone;
30 {4-[(R)-7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-
yl}-piperidin-4-yl-methanone;

1-{4-[(7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-ethanone;

{4-[(6,7-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-piperazin-1-yl-methanone;

5 {4-[(7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-(4-methyl-piperazin-1-yl)-methanone; and

{4-[(7-Bromo-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amino]-piperidin-1-yl}-piperidin-4-yl-methanone.

10 36. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in admixture with an acceptable carrier.

37. The pharmaceutical composition of Claim 36, wherein the compound is suitable for administration to a subject having a disease state which is alleviated by
15 treatment with a M2/M3 muscarinic receptor antagonist.

38. A method of treating a subject which comprises administering to the subject with a disease treatable with a M2/M3 muscarinic antagonist a therapeutically effective amount of one or more compounds of Claim 1.

20

39. The method of Claim 38, wherein the disease state is associated with smooth muscle disorders comprising diseases of the genitourinary or gastrointestinal tract, or of respiratory states.

25 40. The method of Claim 39, wherein the disease state is associated with the genitourinary tract.

41. The method of Claim 40, wherein the disease state comprises overactive bladder, detrusor hyperactivity, urgency, frequency, reduced bladder capacity,
30 incontinence episodes, changes in bladder capacity, micturition threshold,


unstable bladder contractions, sphincteric spasticity, outlet obstruction, outlet insufficiency, pelvic hypersensitivity, idiopathy conditions, or detrusor instability.

42. The method of treatment of Claim 39, wherein the disease state comprises respiratory states.


43. The method of treatment of Claim 42, wherein the disease state comprises respiratory states from allergies or asthma.

44. The method of treatment of Claim 39, wherein the disease state comprises gastrointestinal tract disorders.

45. A process for preparing a compound as claimed in Claim 1 which process comprises reacting a compound having a general formula **d**:



wherein R^1 , R^2 and R^3 are as described in Claim 1,
with a compound of general Formula $R^4C(O)L$, wherein L is a leaving group and R^4 is as described in Claim 1,
to prepare a compound of Formula **I**



wherein R^1 , R^2 , R^3 and R^4 are as described in Claim 1.